CA3235447A1 - Staggered triple lipid-modified nucleic acid compounds - Google Patents
Staggered triple lipid-modified nucleic acid compounds Download PDFInfo
- Publication number
- CA3235447A1 CA3235447A1 CA3235447A CA3235447A CA3235447A1 CA 3235447 A1 CA3235447 A1 CA 3235447A1 CA 3235447 A CA3235447 A CA 3235447A CA 3235447 A CA3235447 A CA 3235447A CA 3235447 A1 CA3235447 A1 CA 3235447A1
- Authority
- CA
- Canada
- Prior art keywords
- unsubstituted
- substituted
- independently
- membered
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163279270P | 2021-11-15 | 2021-11-15 | |
| US63/279,270 | 2021-11-15 | ||
| PCT/US2022/079790 WO2023086979A1 (en) | 2021-11-15 | 2022-11-14 | Staggered triple lipid-modified nucleic acid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235447A1 true CA3235447A1 (en) | 2023-05-19 |
Family
ID=86336682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235447A Pending CA3235447A1 (en) | 2021-11-15 | 2022-11-14 | Staggered triple lipid-modified nucleic acid compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250027082A1 (https=) |
| EP (1) | EP4433064A1 (https=) |
| JP (1) | JP2024543372A (https=) |
| KR (1) | KR20240103016A (https=) |
| CN (1) | CN118215484A (https=) |
| AU (1) | AU2022387688A1 (https=) |
| CA (1) | CA3235447A1 (https=) |
| IL (1) | IL312217A (https=) |
| MX (1) | MX2024005742A (https=) |
| WO (1) | WO2023086979A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120247995A (zh) * | 2018-05-30 | 2025-07-04 | 诺华股份有限公司 | 脂质修饰的核酸化合物和方法 |
| CA3166370A1 (en) * | 2019-11-27 | 2021-06-03 | Dtx Pharma, Inc. | Compounds and methods for the treatment of duchenne muscular dystrophy |
-
2022
- 2022-11-14 JP JP2024527320A patent/JP2024543372A/ja active Pending
- 2022-11-14 IL IL312217A patent/IL312217A/en unknown
- 2022-11-14 CN CN202280074512.5A patent/CN118215484A/zh active Pending
- 2022-11-14 CA CA3235447A patent/CA3235447A1/en active Pending
- 2022-11-14 US US18/708,787 patent/US20250027082A1/en active Pending
- 2022-11-14 KR KR1020247019235A patent/KR20240103016A/ko active Pending
- 2022-11-14 WO PCT/US2022/079790 patent/WO2023086979A1/en not_active Ceased
- 2022-11-14 MX MX2024005742A patent/MX2024005742A/es unknown
- 2022-11-14 EP EP22893903.9A patent/EP4433064A1/en active Pending
- 2022-11-14 AU AU2022387688A patent/AU2022387688A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024005742A (es) | 2024-05-27 |
| CN118215484A (zh) | 2024-06-18 |
| US20250027082A1 (en) | 2025-01-23 |
| EP4433064A1 (en) | 2024-09-25 |
| JP2024543372A (ja) | 2024-11-21 |
| KR20240103016A (ko) | 2024-07-03 |
| IL312217A (en) | 2024-06-01 |
| AU2022387688A1 (en) | 2024-04-11 |
| WO2023086979A1 (en) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5363655B2 (ja) | アンチセンス核酸 | |
| CA2989682A1 (en) | Oligonucleotide compositions and methods thereof | |
| CA3072076A1 (en) | Oligonucleotide compositions and methods thereof | |
| JP7190794B2 (ja) | 核酸医薬及び多分岐脂質の複合体 | |
| CA3037548A1 (en) | Oligonucleotide compositions and methods thereof | |
| JP6542662B2 (ja) | オリゴヌクレオチドアナログのボロン酸結合体 | |
| BR122020018622A2 (pt) | Molécula de ácido nucleico para redução de papd5 e papd7 de mrna para o tratamento de infecção hepatite b | |
| JP2021508689A (ja) | ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド | |
| TW202123973A (zh) | 用於肝臟遞送之GalNAc-寡核苷酸結合物及製造方法 | |
| JP7821737B2 (ja) | 核酸および半減期モチーフを含む化合物 | |
| JP2021508327A (ja) | 新規のチオホスホラミダイト | |
| JP2021505175A (ja) | Fndc3bの発現を調節するためのオリゴヌクレオチド | |
| CA3235447A1 (en) | Staggered triple lipid-modified nucleic acid compounds | |
| CA3235963A1 (en) | Branched triple lipid-modified nucleic acid compounds | |
| JP2021508690A (ja) | ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド | |
| BR122024013151A2 (pt) | Compostos escalonados de ácido nucleico modificado por lipídio triplo, processos de fabricação e usos dos mesmos, célula, composição farmacêutica, e genoma de célula | |
| BR122024015224A2 (pt) | Compostos de ácido nucleico modificado por lipídio triplo ramificados, processos de preparação e usos dos mesmos, célula, composição farmacêutica, e genoma celular | |
| JP2021510295A (ja) | Gsk3b発現を調節するためのオリゴヌクレオチド | |
| WO2025261378A1 (zh) | 一种修饰的核苷化合物及其在寡核苷酸中的应用 | |
| CN121971633A (en) | Compounds comprising nucleic acids and half-life extending motifs | |
| CA3129646A1 (en) | Novel phosphoramidites | |
| JP2021511022A (ja) | Pias4発現を調節するためのオリゴヌクレオチド | |
| JP2021510525A (ja) | Erc1発現を調節するためのオリゴヌクレオチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240717 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241104 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241104 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251023 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251023 |